Related Experiment Video
Updated: Apr 14, 2026
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
Published on: July 20, 2014
Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation
Li-Yan Li1,2, Hong Jiang3, Yang-Min Xie4
1The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, Guangdong, P.R. China.
Abstract:
The paucity of new drugs for the treatment of esophageal squamous cell carcinoma (ESCC) limits the treatment options. This study characterized the therapeutic efficacy and action mechanism of a novel natural macrolide compound F806 in human ESCC xenograft models and cell lines. F806 inhibited growth of ESCC, most importantly, it displayed fewer undesirable side effects on normal tissues in two human ESCC xenograft models. F806 inhibited proliferation of six ESCC cells lines, with the half maximal inhibitory concentration (IC50) ranging from 9.31 to 16.43 μM. Furthermore, F806 induced apoptosis of ESCC cells, contributing to its growth-inhibitory effect. Also, F806 inhibited cell adhesion resulting in anoikis. Mechanistic studies revealed that F806 inhibited the activation of β1 integrin in part by binding to a novel site Arg610 of β1 integrin, suppressed focal adhesion formation, decreased cell adhesion to extracellular matrix and eventually triggered apoptosis. We concluded that F806 would potentially be a well-tolerated anticancer drug by targeting β1 integrin, resulting in anoikis in ESCC cells.
Insights
A new natural compound, F806, shows promise for treating esophageal squamous cell carcinoma (ESCC). It effectively inhibits cancer growth and induces cell death with fewer side effects, offering a potential new therapeutic option.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Limited therapeutic options exist for esophageal squamous cell carcinoma (ESCC).
- Novel drug candidates are urgently needed to improve treatment outcomes for ESCC patients.
Purpose of the Study:
- To investigate the therapeutic efficacy of the natural macrolide compound F806 in esophageal squamous cell carcinoma (ESCC).
- To elucidate the mechanism of action of F806 in ESCC cell lines and xenograft models.
Main Methods:
- In vitro studies using six human ESCC cell lines to determine half maximal inhibitory concentration (IC50).
- In vivo studies using human ESCC xenograft models to assess therapeutic efficacy and side effects.
- Mechanistic studies involving analysis of cell adhesion, apoptosis, and β1 integrin activation.
Main Results:
- F806 demonstrated significant inhibition of ESCC cell proliferation with IC50 values ranging from 9.31 to 16.43 μM.
- F806 induced apoptosis and anoikis in ESCC cells by inhibiting β1 integrin activation and cell adhesion.
- F806 exhibited fewer side effects on normal tissues compared to its anti-cancer effects in xenograft models.
Conclusions:
- F806 is a potential anticancer drug candidate for esophageal squamous cell carcinoma (ESCC).
- F806 targets β1 integrin, leading to anoikis and apoptosis in ESCC cells.
- The compound shows promise as a well-tolerated therapeutic agent for ESCC treatment.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...